Out-licensing: Endocrinology/Endocrine System

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Up-to-date access to technology licensing opportunities worldwide.

Out-licensing
Browse

Licensing opportunities

Displaying 1..5 of 5 - per page
Order by

Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications

Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More

1,2,4-Benzothiadiazine derivatives

1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More

Out-licensing of modified-release gabapentin, a non-hormonal prescription product for the treatment of menopausal hot flushes/flashes and related symptoms associated with cancer therapies.

Exclusive license for use of gabapentin in the above indications in EU, Canada, Australia, New Zealand. US Phase 3 trials of MR-gabapentin for menopause by PharmaNova’s US licensee (Depomed, Inc) will complete in 3Q 2009; Co-promotion in US is possible. More

PDE11A as a Novel Therapeutic Target for Inherited Form of Cushing Syndrome and Endocrine Tumors

Clinical identification of a new disease termed "isolated micronodular adrenocortical disease" (iMAD), as well as the role of PDE11A gene in this disease More

Small-Molecule Modulators of the Thyroid-Stimulating Hormone (TSH) Receptor

A series of low-molecular weight compounds that act as TSH receptor antagonists (inhibitors) or agonists (activators) More

Displaying 1..5 of 5 - per page
Order by

Your selection

Therapeutic target: Endocrinology del; Endocrine system del

Browse By

Industry sector: Animal health; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us